4D Molecular Therapeutics (NASDAQ:FDMT) Posts Earnings Results, Misses Expectations By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) posted its quarterly earnings results on Friday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Trading Up 1.1 %

FDMT opened at $4.53 on Friday. The stock has a fifty day moving average price of $5.22 and a 200 day moving average price of $8.59. 4D Molecular Therapeutics has a 1 year low of $4.20 and a 1 year high of $36.25. The stock has a market cap of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81.

Analyst Ratings Changes

A number of brokerages have recently issued reports on FDMT. Morgan Stanley cut their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th. BMO Capital Markets downgraded 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $40.00 to $15.00 in a report on Monday, January 13th. Leerink Partners decreased their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada lowered their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.